Andrew Baum
Stock Analyst at Citigroup
(2.84)
# 1,870
Out of 4,911 analysts
63
Total ratings
72.09%
Success rate
12.83%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Downgrades: Neutral | $115 → $84 | $84.71 | -0.84% | 14 | May 14, 2025 | |
| PFE Pfizer | Maintains: Neutral | $30 → $29 | $24.79 | +16.98% | 10 | Jan 28, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $65 | $48.43 | +34.21% | 11 | Jan 28, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $36.67 | +9.08% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $190.28 | +12.99% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $812.69 | +10.13% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $9.61 | +4.06% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $37.97 | - | 2 | Jul 5, 2017 |
Merck & Co.
May 14, 2025
Downgrades: Neutral
Price Target: $115 → $84
Current: $84.71
Upside: -0.84%
Pfizer
Jan 28, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $24.79
Upside: +16.98%
Bristol-Myers Squibb Company
Jan 28, 2025
Maintains: Neutral
Price Target: $60 → $65
Current: $48.43
Upside: +34.21%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $36.67
Upside: +9.08%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $190.28
Upside: +12.99%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $812.69
Upside: +10.13%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $9.61
Upside: +4.06%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $37.97
Upside: -